Munich-based Twogee Biotech is a 2024-founded biotechnology startup that offers a predictive enzyme-development platform combining enzyme screening, strain engineering and fermentation to convert low-value biomass residues into higher-value sugars for bio- and synthetic-biology applications. Its technology is designed for straightforward integration into existing industrial processes, helping partners create circular, low-CO₂ value chains while shortening development timelines and reducing scale-up risk. The company has already delivered initial MVPs and completed paid pilot projects with industrial customers, demonstrating early commercial traction. Twogee plans to commercialise its platform through a licensing model that enables customers to produce the enzymes locally, cutting costs and emissions and supporting decentralised production. Proceeds from its recent seed financing will fund further technology development and market rollout. The business has not yet disclosed recurring revenue figures but is backed by both financial and strategic investors, positioning it for its next stage of growth.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026